JPWO2022173670A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022173670A5
JPWO2022173670A5 JP2023547766A JP2023547766A JPWO2022173670A5 JP WO2022173670 A5 JPWO2022173670 A5 JP WO2022173670A5 JP 2023547766 A JP2023547766 A JP 2023547766A JP 2023547766 A JP2023547766 A JP 2023547766A JP WO2022173670 A5 JPWO2022173670 A5 JP WO2022173670A5
Authority
JP
Japan
Prior art keywords
seq
nos
amino acid
set forth
lcdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547766A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506315A5 (https=
JP2024506315A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/015341 external-priority patent/WO2022173670A1/en
Publication of JP2024506315A publication Critical patent/JP2024506315A/ja
Publication of JPWO2022173670A5 publication Critical patent/JPWO2022173670A5/ja
Publication of JP2024506315A5 publication Critical patent/JP2024506315A5/ja
Pending legal-status Critical Current

Links

JP2023547766A 2021-02-09 2022-02-04 コロナウイルスのスパイクタンパク質を標的とする抗体 Pending JP2024506315A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147419P 2021-02-09 2021-02-09
US63/147,419 2021-02-09
PCT/US2022/015341 WO2022173670A1 (en) 2021-02-09 2022-02-04 Antibodies targeting the spike protein of coronaviruses

Publications (3)

Publication Number Publication Date
JP2024506315A JP2024506315A (ja) 2024-02-13
JPWO2022173670A5 true JPWO2022173670A5 (https=) 2025-02-06
JP2024506315A5 JP2024506315A5 (https=) 2025-02-06

Family

ID=80447839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547766A Pending JP2024506315A (ja) 2021-02-09 2022-02-04 コロナウイルスのスパイクタンパク質を標的とする抗体

Country Status (11)

Country Link
US (1) US20240117011A1 (https=)
EP (1) EP4291226A1 (https=)
JP (1) JP2024506315A (https=)
KR (1) KR20230142790A (https=)
CN (1) CN117642178A (https=)
AU (1) AU2022221297A1 (https=)
CA (1) CA3209136A1 (https=)
CL (1) CL2023002326A1 (https=)
IL (1) IL304955A (https=)
MX (1) MX2023009244A (https=)
WO (1) WO2022173670A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4045533T3 (fi) 2020-03-26 2024-02-02 Univ Vanderbilt Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
WO2024040187A2 (en) * 2022-08-19 2024-02-22 The Regents Of The University Of California Sars-cov2 neutralizing single domain antibody constructs
EP4335870A1 (en) * 2022-09-06 2024-03-13 NantCell, Inc. Peptide therapeutics against sars-cov-2 spike protein
WO2024054822A1 (en) * 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
KR102902144B1 (ko) * 2022-11-11 2025-12-19 연세대학교 산학협력단 SARS-CoV-1 검출용 항체 및 이를 이용한 면역친화성 바이오 센서
CN121002058A (zh) * 2022-12-09 2025-11-21 艾布维兹生物公司 针对SARS-CoV-2及其变体的抗体或其片段
WO2024131775A1 (zh) * 2022-12-20 2024-06-27 北京昌平实验室 新型冠状病毒xbb.1.5及相关变异株广谱中和抗体及应用
CN121096424A (zh) * 2024-06-07 2025-12-09 上海欧易生物医学科技有限公司 一种自动处理宏基因组高通量测序数据分箱得到病毒基因组的分析方法、分析系统及应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
DE69332485T2 (de) 1992-08-11 2003-11-13 The President And Fellows Of Harvard College, Cambridge Immunmodulierende peptide
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
DK1032660T3 (da) 1997-11-17 2010-01-18 Micromet Ag Fremgangsmåde til identivicering af bindingsstedsdominans som bevarer evnen til at binde til en epitop
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
CZ302070B6 (cs) 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
US6723538B2 (en) 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
CA2402534C (en) 2000-03-24 2011-05-24 Micromet Ag Mrna amplification
WO2002016414A2 (en) 2000-08-22 2002-02-28 Micromet Ag Composition for the elimination of autoreactive b-cells
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003068822A2 (en) 2002-02-13 2003-08-21 Micromet Ag De-immunized (poly)peptide constructs
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
JP4832719B2 (ja) 2002-04-09 2011-12-07 協和発酵キリン株式会社 FcγRIIIa多型患者に適応する抗体組成物含有医薬
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
KR20060015602A (ko) 2003-05-31 2006-02-17 마이크로메트 에이지 EpCAM 에 대한 이중 특이성 항체를 포함하는약학조성물
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
DE602004030811D1 (de) 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP2468774A3 (en) 2005-04-18 2013-01-02 Amgen Research (Munich) GmbH Antibody neutralizers of human granulocyte macrophage colony stimulating factor
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
DK1976886T3 (en) 2005-12-16 2015-03-02 Amgen Res Munich Gmbh Means and methods for the treatment of tumor diseases
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
CR20220552A (es) * 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
JP2023528826A (ja) * 2020-05-29 2023-07-06 ウニヴェルジテート・ツー・ケルン Sars関連コロナウイルスに対する中和抗体

Similar Documents

Publication Publication Date Title
CN115052895B (zh) 抗SIRPα抗体及其用途
JP2025067915A5 (https=)
JP2020530272A5 (https=)
RU2020130795A (ru) Нейтрализующие антитела к env вич-1 и их применение
JP2019527553A5 (https=)
CN115605511A (zh) 抗tigit的抗体、其制备方法和应用
IL314799A (en) Human monoclonal antibodies that broadly target coronaviruses
JP2020534830A5 (https=)
JP2024024114A5 (https=)
CN109721656B (zh) 靶向rankl的治疗性抗体
CN106243223B (zh) 抗人pdl1抗体及其用途
JPWO2022256563A5 (https=)
JPWO2022173670A5 (https=)
IL315960A (en) Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
KR20240031229A (ko) 알파-시누클레인병증 치료용 항체
JPWO2023154824A5 (https=)
JP2020533022A5 (https=)
JPWO2021133723A5 (https=)
CN112969715A (zh) 一种抗cd47抗原结合蛋白及其应用
JPWO2022268192A5 (https=)
JPWO2019177854A5 (https=)
JPWO2021003297A5 (https=)
JPWO2020102555A5 (https=)
IL311153A (en) Bispecific antibody and its use
JPWO2021147829A5 (https=)